Medicus Pharma (MDCX) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medicus Pharma (MDCX) has outperformed Psyence Biomedical (PBM) over the past year, losing 96.3% versus a loss of 96.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | PBM |
|---|---|---|
| Share price | $0.0921 | $4.97 |
| Market cap | $138.07K | — |
| 1-day change | -9.62% | -2.93% |
| YTD return | -93.98% | -83.10% |
| 1-year return | -96.33% | -96.56% |
| EPS (TTM) | $-119.00 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $139.00 | $150.78 |
| 52-week low | $0.084 | $1.92 |
| Distance from 52-week high | -99.93% | -96.70% |
| Analyst consensus | none | — |
| Avg. price target upside | +4785.99% | — |
| Average volume | 92.96K | 94.85K |
| Shares outstanding | 1.50M | — |
| Employees | 16 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
MDCX vs PBM FAQ
Which stock has performed better over the past year, MDCX or PBM?
MDCX returned -96.33% over the past 12 months, compared with -96.56% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Medicus Pharma and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.